Study Evaluating the Tolerability of Bifeprunox in Healthy Subjects

Safety and tolerability study in healthy volunteers

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Healthy male 18-50 years
Nonlactating female 18-50 years

Treatment and study plan

Bifeprunox

Drug

oral tablet once daily

Primary outcomes

Tolerability

Time frame: 28 days

Secondary outcomes

Safety

Time frame: 28 days

Sponsors and collaborators

Lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

Industry

Registry information

Official study title

A 3-Part, Randomized, Multiple-Dose, Sequential Design Study of Bifeprunox in Healthy Subjects in Order to Establish a Titration Regimen With an Improved Tolerability Profile

Important dates

Study start: 2007
Primary completion: 2008
Study completion: 2008
First posted: Dec 27, 2007
Registry last updated: Jul 10, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed